BerGenBio Announces Update From Investigational Phase II Trials Assessing Bemcentinib In Hospitalised COVID-19 Patients
Data receipt is ongoing and evaluation of efficacy data is underway
Exploratory analyses are looking to define subsets of patients with baseline markers indicative of increased disease severity with the potential for greater benefit
Bemcentinib was well tolerated throughout both studies, in the ACCORD2 study there was a numerically lower number of deaths up to day 29 in the bemcentinib arm (1 of 28 with bemcentinib + standard of care vs 5 of 32 in patients treated with standard of care alone); in BGBC020 it was 2 vs 3 respectively
More detailed top line data expected to report in May
GlucoModicum s non-invasive glucose monitoring technology performs 13x better than previous needle-free approaches
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
GlucoModicum s non-invasive glucose monitoring technology performs 13x better than previous needle-free approaches
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
BerGenBio Presents Preclinical COVID-19 Data at Annual Conference on Retroviruses and Opportunistic Infections (CROI 2021)
BERGEN, Norway, March 6, 2021 /PRNewswire/ BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, today delivered a Science Spotlight oral presentation on preclinical COVID-19 data at the annual Conference on Retroviruses and Opportunistic Infections (CROI), taking place from 6-10 March 2021.
The presentation was led by BerGenBio s collaborator, Professor Wendy Maury, Professor of Microbiology and Immunology at the University of Iowa (Iowa City, USA), who presented data showing that AXL enhances the ability of SARS-CoV-2 to infect cell lines from the human airway, increasing the amount of virus measured in those cells. Treating the human cell lines, Vero E6 and human ACE2-expressing A549 lung cancer cell lines, with the AXL kinase inhibitor, bemcentinib reduces th
Bergenbio Closes Recruitment Into Trial Assessing Bemcentinib In Covid-19 Patients
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.